Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs.

Front Oncol · 2026 · PMC13078995 · PMID 41994630

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

In addition, although the non-squamous subgroup in our analysis showed a borderline result (p=0.064), this finding may still indicate a possible trend toward benefit in non-squamous patients.

also in 939 other papers

did not reach statistical significanceno p-value reported

However, in patients with PD-L1≥50%, the intervention group demonstrated superior PFS compared with the control group (PD-L1<1%: HR = 0.83, 95%CI: 0.63-1.07; 1%≤PD-L1<49%: HR = 0.59, 95%CI: 0.34-1.03; PD-L1≥50%: HR = 0.78, 95%CI: 0.63-0.96, respectively).Within the histological subtype subgroup, the intervention group demonstrated superior PFS compared with the control group in patients with non-squamous NSCLC (HR = 0.82, 95%CI: 0.66-1.01, p=0.064), though this difference did not reach statistical significance.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.